Nodal involvement in patients with small, clinically node-negative HER2-positive breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy
The proportion of patients with ypN + after NAST combined with FDG-PET/CT was only 6.1 %. Neoadjuvant treatment can be a safe treatment strategy for patients with stage I HER2+ BC.
Authors
- Marcel P. M. Stokkel (ORCID: https://orcid.org/0000-0002-8131-5690)
- Caroline A. Drukker (ORCID: https://orcid.org/0000-0003-3477-5499)
- Josefien P. van Olmen (ORCID: https://orcid.org/0000-0001-6971-2688)
- Marleen Kok (ORCID: https://orcid.org/0000-0001-9043-9815)
- Frederieke van Duijnhoven (ORCID: https://orcid.org/0000-0003-3694-4049)
- Marie-Jeanne TFD. Vrancken Peeters
- Veerle Geurts (ORCID: https://orcid.org/0000-0002-1915-3811)
Institutions
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
Publication Details
- Journal
- The Breast
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.breast.2024.103822
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Gilead Sciences
- Daiichi Sankyo Europe